Stage IIIC Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01134614Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01708941Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01950390Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment